Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences Inc. (noted as Lunai Bioworks Inc. in metadata) on October 30, 2018. The report discloses a corporate governance change involving the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to director compensation.
- Director Compensation: $60,000 annual cash and $75,000 annual stock options for the newly appointed director.
Material Changes
The Board of Directors increased its size from 6 to 7 members. Luc Debruyne was appointed as a director effective immediately on October 30, 2018. No other material transactions or changes were reported.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. It confirms there are no undisclosed arrangements or related-party transactions requiring disclosure under Item 404(a) of Regulation S-K regarding the new director.
Investor Verification Checklist
- Verify the correct registrant name (Enochian Biosciences Inc. vs. Lunai Bioworks Inc.).
- Confirm the total number of board seats is now 7.
- Review the impact of the $135,000 annual compensation package on future equity dilution and cash burn.
- Check for any subsequent filings regarding Mr. Debruyne's background or conflicts of interest.